Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP7 | P09237 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL700919 | 0.89 | BDKRB1 (0.41) | RAB9ANPC1BDKRB1FKBP1A | |
| SCHEMBL700918 | 0.89 | BDKRB1 (0.41) | RAB9ANPC1BDKRB1FKBP1A | |
| SCHEMBL3764050 | 0.89 | BDKRB1 (0.41) | RAB9ANPC1BDKRB1MMP1MMP3 | |
| SCHEMBL3764045 | 0.89 | BDKRB1 (0.41) | RAB9ANPC1BDKRB1MMP1MMP3 | |
| SCHEMBL2567152 | 0.88 | BDKRB1 (0.40) | RAB9ANPC1BDKRB1FKBP1A | |
| SCHEMBL2563013 | 0.87 | KMT2A (0.42) | RAB9ANPC1KMT2A | |
| SCHEMBL2568392 | 0.86 | BDKRB1 (0.45) | RAB9ANPC1BDKRB1KMT2A | |
| SCHEMBL2560595 | 0.85 | RAB9A (0.43) | RAB9ANPC1BDKRB1PAX8 | |
| SCHEMBL3441446 | 0.85 | RAB9A (0.43) | RAB9ANPC1BDKRB1PAX8 | |
| SCHEMBL2568129 | 0.85 | ACHE (0.48) | RAB9ANPC1BDKRB1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253669-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | RAB9A 2485/4885NPC1 2399/4885BDKRB1 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.